Moxifloxacin Krka (Moxifloxacin)

Moxifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition prevents the resealing of DNA strands, leading to bacterial cell death and a bactericidal effect against a broad range of Gram‑positive and Gram‑negative bacteria.

The specific dose and treatment duration of Moxifloxacin Krka are determined by the prescribing clinician based on the infection type, severity, patient age, renal function, and other clinical factors. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Safety data for moxifloxacin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under direct medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and better activity in respiratory infections compared with some older fluoroquinolones. It also has a once‑daily dosing schedule, but shares class‑related safety considerations such as tendon toxicity and QT prolongation, which must be weighed against alternative agents.

Moxifloxacin Krka tablets should be stored at room temperature, below 25 °C, in the original blister pack or container to protect from moisture and light. Keep out of reach of children and do not use if the packaging is damaged.

Moxifloxacin Krka is taken orally, usually with a full glass of water. It may be taken with or without food, but antacids containing aluminum or magnesium should be spaced at least two hours apart to avoid reduced absorption.

Serious risks include tendon rupture (especially Achilles), QT interval prolongation leading to arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and hepatic dysfunction. Patients should seek immediate medical attention if they experience sudden tendon pain, palpitations, severe rash, or persistent diarrhea.

Moxifloxacin Krka should be avoided in patients with a known hypersensitivity to fluoroquinolones, a history of tendon disorders related to fluoroquinolone use, those taking other QT‑prolonging drugs without monitoring, and individuals with uncontrolled epilepsy or severe hepatic impairment unless benefits clearly outweigh risks.